Germany’s BioNTech, Pfizer’s partner in COVID-19 vaccines, said the two companies would start tests on humans of next-generation shots that protect against a wide variety of coronaviruses in the second half of the year.
Their experimental work on shots that go beyond the current approach include T-cell-enhancing shots, designed to primarily protect against severe disease if the virus becomes more dangerous, and pan-coronavirus shots that protect against the broader family of viruses and its mutations.
In presentation slides posted on BioNTech’s website for its investor day, the German biotech firm said its aim was to “provide durable variant protection.”
The two partners, makers of the Western world’s most widely used COVID-19 shot, are currently discussing with regulators enhanced versions of their established shot to better protect against the Omicron variant and its sub lineages.
The virus’ persistent mutation into new variants that more easily evade vaccine protection, as well as waning human immune memory, have added urgency to the search by companies, governments and health bodies for more reliable tools of protection.
As part of a push to further boost its infectious disease business, BioNTech said it was independently working on precision antibiotics that kill superbugs that have grown resistant to currently available anti-infectives.
BioNTech, which did not say when trials could begin, is leaning on the technology of PhagoMed, which it acquired in October last year.
The Vienna-based antibiotics developer has done work on enzymes, made by bacteria-killing viruses, that break through the bacterial cell wall.
Drug-resistant infections are on the rise, driven by antibiotic overuse and leaks into the environment in antibiotics production.
Public health researchers put the combined number of people dying per year from antibiotic-resistant infections in the United States and the European Union at close to 70,000.
Pfizer-BioNTech begin omicron COVID-19 vaccine trial: StatementPfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their omicron-specific COVID-19 vaccine in ... Coronavirus
Pfizer, BioNTech ask US regulators to approve COVID-19 vaccine for kidsPfizer Inc and BioNTech said on Thursday they had asked US regulators to approve emergency use of their COVID-19 vaccine for children aged from five ... Coronavirus
Pfizer/BioNTech COVID-19 vaccine effectiveness drops after 6 months: StudyThe effectiveness of the Pfizer Inc /BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47 percent from 88 percent six months ... Coronavirus
Pfizer/BioNTech bid for COVID-19 booster doses premature, more data needed: ExpertsPfizer’s push for health regulators to authorize a third dose of its COVID-19 shot is not yet backed by evidence, despite the fast-spreading Delta ... Coronavirus